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ABSTRACT
Mutations or inactivation of parkin, an E3 ubiquitin
ligase, are associated with familial form or sporadic
Parkinson’s disease (PD), respectively, which mani-
fested with the selective vulnerability of neuronal cells in
substantia nigra (SN) and striatum (STR) regions. How-
ever, the underlying molecular mechanism linking par-
kin with the etiology of PD remains elusive. Here we
report that p62, a critical regulator for protein quality
control, inclusion body formation, selective autophagy
and diverse signaling pathways, is a new substrate of
parkin. P62 levels were increased in the SN and STR
regions, but not in other brain regions in parkin knock-
out mice. Parkin directly interacts with and ubiquitinates
p62 at the K13 to promote proteasomal degradation of
p62 even in the absence of ATG5. Pathogenic mutations,
knockdown of parkin or mutation of p62 at K13 pre-
vented the degradation of p62. We further showed that
parkin deﬁciency mice have pronounced loss of
tyrosine hydroxylase positive neurons and have worse
performance in motor test when treated with 6-hydrox-
ydopamine hydrochloride in aged mice. These results
suggest that, in addition to their critical role in regulating
autophagy, p62 are subjected to parkin mediated pro-
teasomal degradation and implicate that the dysregula-
tion of parkin/p62 axis may involve in the selective
vulnerability of neuronal cells during the onset of PD
pathogenesis.
KEYWORDS parkin, sequestosome1/p62, ubiquitin,
substantia nigra
INTRODUCTION
Parkinson’s disease (PD) is one of the most common neu-
rodegenerative diseases affecting over 2% of the population
over 65 years of age. The selective loss of dopaminergic
neurons that project from the midbrain substantia nigra (SN)
to the striatum (STR) could account for the movement dis-
order symptom in PD (Ishikawa and Tsuji, 1996; Thomas and
Beal, 2007). Sporadic PD or “classical parkinsonism”
accounts for the majority of the disease and is multisystem
neurodegenerative disorders, morphologically characterized
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by Lewy bodies (LBs) formation. The formation of LBs
includes the stepwise condensation to ubiquitinated dense
ﬁlamentous inclusions with incorporation of alpha-synuclein
(Singleton et al., 2003; Spillantini et al., 1997) or p62
(Nakaso et al., 2004), which ultimately invoke the death and
disappearance of the involved neurons, and ubiquitination
seems to increase aggregation and neurotoxicity of alpha-
synuclein in cultured human dopaminergic cells (Lee et al.,
2008; Rott et al., 2008). A number of genes have been
identiﬁed, and investigation of the underlying mechanisms of
how these genes function has provided tremendous insights
into the pathogenesis of both familial and sporadic PD
(Bossy-Wetzel et al., 2004; Dawson, 2007; Dawson and
Dawson, 2003; Farrer, 2006). In particular, mutations in
parkin represent one of the major causes of early-onset
familial PD (Biskup et al., 2008; Kitada et al., 1998; Lesage
and Brice, 2009); It was thus proposed that mutations in
parkin, an E3 ubiquitin ligase which ubiquitinates and
degrades a diverse array of substrates, would cause accu-
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Figure 1. P62 level is negatively correlated with parkin activity in vivo. (A) P62 is reduced in STR and SN of parkin+/+, but not
parkin−/− mice under hypoxic stress. parkin+/+and parkin−/− mice, 18-month-old male C57Bl/6, were treated with 8% oxygen
conditions for 0 (control) or 7 days. The striatum (STR), substantia nigra (SN), Hippocampus (HIP), frontal cortex (CTX) and
cerebellum (CB) regions were isolated and homogenized in lysis buffer. Western blotting was performed to examine the level of
indicated proteins. (B) P62 level increased in parkin−/− mice in STR and SN regions. The STR and SN regions from 8-week-old male
C57Bl/6 mice brain were further isolated and homogenized in lysis buffer, and Western blotting was performed to examine the level of
p62 (A). (C) Relative protein levels of p62 of individual mice in (1B) were quantiﬁed according to the results of ten independent blots
and normalized to β-actin. (D) The mRNA levels detected by qPCR in mice tissues were described in Fig. 1B and 1D. The intensity of
bands was measured with Image J software in B, mean ± SEM, from 3 independent experiments, one-way ANOVA, the P-value were
indicated ﬁgures.
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insufﬁcient E3 ligase activity for ubiquitin-proteasomal
dependent protein turnover (Kahle and Haass, 2004; Li and
Guo, 2009; Sriram et al., 2005). However, a few of known
substrates were found to be accumulated in parkin deﬁcient
mice brain or in disease phenotypes, and the molecular link
of how mutation of parkin leads to the etiology of PD remains
elusive. Recent studies have revealed that parkin plays
general role for mitochondrial motility and mitochondrial
quality (Bingol et al., 2014; Gegg et al., 2010; Matsuda et al.,
2010; Narendra et al., 2008; Tanaka et al., 2010) through
modulating the stability of Miro (Wang et al., 2011b) and
many other mitochondrial proteins (Chen and Dorn, 2013;
Gegg and Schapira, 2011). It is thus proposed that mutation
of parkin could results in mitochondrial dysfunction, which
may causally link with the pathogenesis of PD. However,
knockout of parkin in mice could not faithfully recapitulate the
PD phenotype, raising the question of the physiological
function and the pathologic role of parkin in PD (Dawson and
Dawson, 2010; Johnson et al., 2012; Shin et al., 2011).
P62, also known as sequestosome 1, is a shuttle protein
transporting polyubiquitinated proteins for both the protea-
somal and autophagy/lysosomal dependent degradation
(Komatsu et al., 2007; Pankiv et al., 2007; Seibenhener
et al., 2004; Wooten et al., 2008). P62 and ubiquitinated
proteins are conserved markers of neuronal aging, aggre-
gate formation and progressive autophagic defects (Bartlett
et al., 2011). In particular, p62 was commonly detected in
ubiquitinated protein aggregates in neuronal diseases
including LBs in PD, neuroﬁbrillary tangles in Alzheimer’s
disease, Huntington aggregates in Huntington’s disease,
and skein-like inclusions in amyotrophic lateral sclerosis
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Figure 2. Parkin mediates the degradation of p62 by both proteasomal and autophagic pathway. (A) Knockdown of parkin
increases p62 levels. Immunoblot analysis of parkin and p62 protein levels in SH-SY5Y cells transfected with shRNA speciﬁcally
targeting two different regions of parkin mRNA. (B) Parkin-mediated p62 degradation can be inhibited by both proteasomal and
autophagic inhibitors. SH-SY5Y cells were transfected with GFP or GFP-parkin for 24 h before treatment with inhibitors: MG132
(5 μmol/L), Baﬁlomycin A1 (20 nmol/L), 3-MA (10 mmol/L), Chloroquine (100 μmol/L), and PMSF (100 μmol/L) using DMSO as
vehicle control. Cells were then harvested and immunoblotted with anti-p62 and anti-GFP antibodies. β-Actin was used as a loading
control in the Western blotting analysis. (C) MG132 inhibited parkin induced p62 degradation. Cells were treated and analyzed as that
in Fig. 2B in the presence or absence of 5 μmol/L MG132. (D) Wild-type, but not disease causing parkin mutants, reduces p62 levels.
Cells were transfected with indicated plasmids for 24 h, then cell lysates were subjected to Western blotting by the anti-p62 and anti-
GFP antibodies. (E) Immunostaining of Myc or parkin-Myc (red) and p62 (green) in SH-SY5Y cells transfected with Myc or parkin-Myc
for 24 h. MG132 were added 8 h before ﬁxed for assay the parkin and p62 protein levels. (F) Quantiﬁcation of the cells with low level
of p62 from Myc or parkin-Myc expression cells as shown in Fig. 2E. Mean ± SEM; n = 100 cells from 3 independent experiments,
two-way ANOVA.
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2004; Zatloukal et al., 2002). P62 shuttles misfolded proteins
to the aggresome and autophagosome (Bjorkoy et al., 2006;
Kirkin et al., 2009; Pankiv et al., 2010). Mutations in p62
have been linked with the occurrence of familial and sporadic
amyotrophic lateral sclerosis (Fecto et al., 2011; Rubino
et al., 2012). Furthermore, knockout of the p62 protein alone
leads to neuropathological lesions including the accumula-
tion of hyperphosphorylated tau and neuroﬁbrillary tangles,
synaptic deﬁciencies with loss of working memory and
neuronal apoptosis (Babu et al., 2005; Wooten et al., 2008).
It is thus crucial to maintain a homeostatic level of p62 for
normal cellular functions. Dysregulation of p62 could result in
the perturbation of cell signaling and accumulation of dam-
aging protein aggregates, leading to neuronal loss and
pathogenesis of neurodegenerative diseases. In an effort to
understand whether and how parkin deﬁciency leads to the
dysregulated mitochondrial dynamics and mitochondrial
quality, we were interested to ﬁnd that p62 is a new substrate
of parkin and p62 is selectively accumulated in dopamingeric
neuronal cells in parkin deﬁcient mice. Our results showed
that parkin plays a critical role for regulating p62 stability and
implied that dysregulation of parkin/p62 axis could account
for the selective vulnerability during pathogenesis of PD.
RESULTS
P62 level is negatively correlated with parkin activity
Neuronal cells in the brain are highly sensitive to oxygen for
energy production and neuronal activity. We thus were
interested to measure the mitochondrial protein levels could
change in response to hypoxic treatments in vivo. We ﬁrst
treated the mice for 7 days in 8% oxygen chamber and
isolated different regions of brain, including the striatum
(STR), substantia nigra (SN), hippocampus (HIP), frontal
cortex (CTX) and cerebellum (CB), and then compared the
protein levels of a number of mitochondrial and autophagy
markers before and after hypoxic treatment. Mitochondrial
proteins such as Mfn1/2, Drp1 in STR, HIP and SN were
signiﬁcantly reduced in wild-type mice, while other mito-
chondrial proteins such as VDAC1, TIMM23, COX4 were
maintained. However, no changes of Drp1 and Mfn1/2 levels
were observed in other regions including the cerebellum and
the frontal cortex (Fig. 1A). Given Mfn1/2 and Drp1 are
known substrates of parkin, we wondered that parkin may be
involved in selectively degradation of Mfn1/2 and Drp1 in
STR and SN regions and thus further compared the protein
levels of a number of mitochondrial and autophagy markers
in wild-type and germline parkin exon 3 knockout mice
(parkin−/−) (Goldberg et al., 2003). The reduction of Mfn1/2,
Drp1 protein levels in STR and SN regions were largely
blocked in parkin deﬁcient mice (Fig. 1A). Interestingly, we
found that p62 levels were also reduced in STR, SN and HIP
regions in response to hypoxia in wild-type mice, similar to
the known mitochondrial substrates of parkin, while its pro-
tein levels were maintained in other brain regions and in
parkin deﬁcient mice (Fig. 1A). Careful examination of p62
levels revealed that there was an increase of p62 levels in
the STR and SN of parkin−/− mice brain compared to controls
(Fig. 1B and 1C), while the other regions of the brain
including the HIP, the CB and CTX exhibited no such
increase (Fig. S1). Real-time PCR analysis showed that
mRNA levels of p62 are reduced in the STR, CB and CTX,
and there were no signiﬁcant changes in the SN and HIP
regions (Fig. 1D). These data demonstrate that parkin is
Figure 3. Parkin mediated the degradation of p62 in
Atg5−/− MEF cells. (A) Cycloheximide (CHX)-chase assay
for the half-life of p62 in SH-SY5Y cells. Top panel, SH-
SY5Y cells were transfected with GFP or GFP-parkin for
24 h, and then treated with CHX (100 μg/mL) for the
indicated time, and Western blotting detected the indicated
antibodies. Bottom panel, the level of remaining p62 at
different time points was normalized to β-actin from 3
separate experiments. (B) Parkin decreases the steady-
state levels of p62 in CHX-chase experiments in SH-SY5Y
cells can be blocked by MG132. Top panel, SH-SY5Y cells
were transfected with GFP or GFP-parkin for 24 h, and
then treated with CHX (100 μg/mL) for the indicated time
and 5 μmol/L MG132 for 8 h, and Western blotting
detected the indicated antibodies. Bottom panel, the level
of remaining p62 at different time points was normalized to
β-actin and/or p62 levels at time 0 from 3 separate
experiments. (C) P62 and its LIR mutant can be degraded
in Atg5−/− MEF cells. Atg5−/− MEF cells were co-trans-
fected with GFP or GFP-parkin and FLAG-p62 or FLAG-
p62 LIR deletion mutant for 24 h. Cells were then
harvested and Western blotted with anti-FLAG or anti-
GFP antibodies. (D) P62 and its LIR mutant can be
degraded in p62−/− MEF cells. P62−/− MEF cells were co-
transfected with GFP or GFP-parkin and FLAG-p62 or
FLAG-p62 LIR deletion mutant for 24 h. Cells were then
harvested and Western blotted with anti-FLAG or anti-GFP
antibodies. (E) CHX-chase assay for the half-life of p62 in
Atg5−/− MEF cells. Top panel, Atg5−/− MEF cells were
transfected with GFP or GFP-parkin for 24 h. Cells were
then treated with CHX (100 μg/mL) for the indicated time,
and Western blotting was performed with anti-p62 or anti-
GFP antibodies. Bottom panel, the level of remaining p62
at different time points was normalized to p62 levels at time
0 from 3 separate experiments. (F) The decrease in the
steady-state levels of p62 by parkin in CHX-chase exper-
iments in Atg5−/−MEF cells can be blocked by MG132. Top
panel, Cells was then treated with CHX (100 μg/mL) for the
indicated time and 5 μmol/L MG132 for 8 h, and Western
blotting was performed with anti-p62 or anti-GFP antibod-
ies. Bottom panel, the level of remaining p62 at different
time course was normalized to β-actin from 3 separate
experiments. (The intensity of bands was measured with
Image J software. mean ± SEM, from 3 independent
experiments, one-way ANOVA, *P < 0.05 compared with
control group).
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involved in regulating mitochondrial protein levels in
response to hypoxia in dopamingeric neuronal cells, and the
protein levels of p62 are negatively correlated with the
expression of parkin in the SN and STR regions that have
selective vulnerability in PD.
Parkin regulates p62 levels via a proteasomal-
dependent pathway
Previous reports including ours have shown that parkin is a
potent E3 ligase that mediates ubiquitination and proteaso-
mal-dependent degradation of its substrates (Burchell et al.,
2013; Ko et al., 2006; Sarraf et al., 2013; Wang et al., 2011a).
We were thus prompted to understand if parkin promoted the
proteasomal degradation of p62 in addition to its well-docu-
mented autophagic degradation. We ﬁrst knocked down
parkin by speciﬁc shRNA in SH-SY5Y cells, a neuroblas-
toma cell line that expresses endogenous parkin, and found
that there was an accumulation of p62 when parkin was
knocked down (Figs. 2A and S2). Conversely, overexpres-
sion of wild-type parkin signiﬁcantly reduced the levels of
p62, but not in those cells that expressed the vector alone
(Fig. 2B–F). The disease-causing mutations in parkin with
impaired E3 ligase activity (Sriram et al., 2005) failed to
induce the reduction of p62 levels (Fig. 2D), indicating that
the level of p62 is dependent on the E3 ligase activity of
parkin. Consistent with previous reports (Ichimura and
Komatsu, 2010; Komatsu and Ichimura, 2010), we found that
the autophagic inhibitors Baﬁlomycin A1 (BA1), 3-MA and
Chloroquine could also inhibit the reduction of p62 when
wild-type parkin was expressed. MG132, a proteasomal
inhibitor, could also potently inhibit p62 reduction when
parkin is ectopically expressed (Fig. 2B and 2C).
Immunoﬂuorescent image analysis further conﬁrmed that
overexpression of parkin could reduce the levels of p62,
which can be prevented by MG132 (Fig. 2E and 2F). To
further substantiate this ﬁnding, we performed a cyclohex-
imide (CHX)-chase assay and found a striking decrease of
the p62 half-life in cells overexpressing GFP-parkin in SH-
SY5Y cells, which can be inhibited by MG132 (Fig. 3A and
3B). Collectively, these data suggest that p62 levels can be
down-regulated by both the autophagic and the proteaso-
mal-dependent pathway.
To further ascertain the proteasomal-dependent degra-
dation of p62 by parkin, the Agt5−/− MEF cells (Fig. S3), in
which autophagic activity is abrogated, were employed to
detect the p62 protein. We transfected Agt5−/− MEF cells
with wild-type p62 or a LIR deletion mutant, which was
reported to mediate its interaction with LC3 for autophagic
degradation, and found that the protein level of p62 or its LIR
deletion mutant were signiﬁcantly reduced when parkin is
expressed in these cells (Fig. 3C). The degradation of p62
and its LIR deletion mutant was also evident when p62 and
parkin were expressed in p62−/− MEF cells (Figs. 3D and
S3). The CHX-chase assay further revealed a signiﬁcant
decrease of the p62 half-life in cells overexpressing GFP-
parkin in Atg5−/− MEF cells, which can be inhibited by
MG132 (Fig. 3E and 3F). Taken together, we conclude that
parkin functions as an E3 ligase to mediate the proteasomal
degradation of p62, or in other words, p62 is a novel sub-
strate of parkin.
Parkin interacts with and ubiquitinates p62
for its degradation
To understand the mechanisms of parkin mediated protea-
somal degradation of p62, we ﬁrst checked if these two
molecules interact with each other. Co-immunoprecipitation
analysis showed that endogenous p62 interacts with
endogenous parkin (Fig. 4A and 4B). Pull-down analysis of
recombinant MBP-parkin with recombinant p62 further
showed that their interaction was direct (Fig. 4C). Ectopically
Figure 4. Parkin interacts with p62 in vivo and in vitro.
(A) SH-SY5Y cells were harvested and the cell lysates
were subjected to immunoprecipitation with an anti-p62
antibody or an IgG control, and the immunoprecipitates
were examined by Western blotting using an anti-parkin
antibody. (B) P62+/+ or p62−/− MEF cells were transfected
with GFP-parkin for 24 h, and cell lysates were subjected
to immunoprecipitation with an anti-p62 antibody or an IgG
control, and the immunoprecipitates were examined by
Western blotting using anti-GFP or anti-p62 antibodies.
(C) In vitro translated p62 was incubated with bacterially
puriﬁed MBP-parkin or MBP immobilized on MBP beads,
and Western blotting was performed to detect the p62
protein by using the anti-p62 antibodies. (D) 293T cells
were transfected with GFP-parkin or GFP (control), and
immunoprecipitation and Western blotting were performed
to examine the interaction between GFP-parkin and
endogenous p62. (E) 293T cells were co-transfected with
FLAG-p62 and GFP-parkin or parkin mutants, and
immunoprecipitation and Western blotting were performed
to examine the interaction between p62 and parkin or
parkin mutants. (F) Top panel, schematic representation of
various deletion mutants of GFP-parkin, including the
Linker domain deletion mutant, ΔLinker; RING1 deletion
mutant, ΔRING1; RING2 deletion mutant, ΔRING2; RING1
and RING2 double deletion mutant, ΔRING; Linker and
double RING ﬁnger deletion mutant, ΔL-R. Bottom panel,
293T cells were co-transfected with FLAG-p62 and GFP-
parkin or parkin mutants, and immunoprecipitation and
Western blotting were performed to examine the interac-
tion between p62 and parkin. (G) Top panel, schematic
representation of various deletion forms of FLAG-p62,
including PB1 domain deletion mutant, ΔPB1; LIR deletion
mutant, ΔLIR; UBA deletion mutant, ΔUBA. Bottom panel,
293T cells were co-transfected with GFP-parkin and
FLAG-p62 or p62 deletion mutants, and immunoprecipita-
tion and Western blotting were performed to examine the
interaction between p62 and parkin.
c




























































































































































































































































































+/+ +/+ -/-Mr (K)
GFP-parkin
GFP-parkin































-- - - - -






























































































































































- - - - -




- - - -
- - - - -
-
+









































+ + + +






















































+ + + +
+ -
- - +

















Parkin promotes proteasomal degradation of p62 RESEARCH ARTICLE
121
expressed GFP-parkin, but not GFP itself, could interact with
endogenous p62 (Fig. 4D). Although pathological mutations
of parkin failed to induce the reduction of p62 levels, they still
interact with p62 in cells (Fig. 4E). Domain mapping indi-
cates that both the RING1 and RING2 domains, which
mediate the E3 ligase activity, and the Linker domain of
parkin were required for binding to p62 via its PB1 domain
(Fig. 4F and 4G).
We next examined whether parkin is able to ubiquitinate
p62 for its subsequent degradation. Knockdown of parkin in
SH-SY5Y cells by speciﬁc shRNA could signiﬁcantly reduce
the ubiquitination of p62 (Fig. 5A). Also, the level of ubiqui-
tinated p62 was signiﬁcantly higher in the midbrain of wild-
type mice than that in parkin−/− mice (Fig. 5B). P62 is
ubiquitinated by wild-type parkin, but not by known disease-
causing mutants (Fig. 5C and 5D). Furthermore, a Linker-
RING ﬁnger deletion mutant parkin that fails to interact with
p62 is also unable to mediate the ubiquitination of p62
(Fig. 5C). Similarly, the PB1 deletion mutant of p62, which
does not interact with parkin, is not ubiquitinated, but not
found in either UBA or LIR domain deletion (Fig. 5E). These
data suggest that p62 is an authentic substrate of parkin in
both cell and animal model systems.
P62 is ubiquitinated at K13 site for proteasomal
degradation
To directly conﬁrm that p62 is directly ubiquitinated by parkin,
we carried out in vitro ubiquitination assay and found that
in vitro puriﬁed parkin ubiquitinates p62 in the presence of
E1, E2, ubiquitin and ATP. These data demonstrate that the
ubiquitination of p62 is speciﬁcally mediated by parkin, while
the disease causing mutants that have impaired E3 ligase
activity fail to ubiquiniate p62 for its subsequent degradation
(Fig. 5F). Immunoprecipitation analysis revealed that parkin
was able to induce the poly-ubiquitination of p62 in the
presence of wild-type or K48 ubiquitin, but signiﬁcantly
reduced in the presence of K29 or K63 ubiquitin (Fig. 5G).
This experimental result suggests that parkin mediates the
poly-ubiuqitination of p62 mainly via K48-linked ubiquitin
chains for proteasomal degradation, while K63 ubiquitin
modiﬁcation occurs to a lesser extent (Fig. 5G).
To further demonstrate that parkin ubiquitinates p62, we
sought to determine the unique site of ubiquitination of p62
by parkin. We transfected 293T cells with HA-Ubiquitin (HA-
UB), GFP-parkin and FLAG-p62 and immunoprecipitated
with anti-FLAG antibody, and immunoprecipitates were fur-
ther analyzed by mass spectrometry, the mass results
showed that both K13 and K420 are ubiquitinated. To con-
ﬁrm that these K13 and K420 residues were the sites of
ubiquitination by parkin, we mutated K13 or K420 to arginine
and co-transfected these mutants with GFP-parkin in 293T
cells. We found that both wild-type p62 and the p62 K420R
mutant, but not the p62 K13R mutant, are ubiquitinated by
parkin (Fig. 5H). Importantly, we showed that the protein
levels of the p62 K13R mutant, but not wild-type p62 or the
p62 K420R mutant, were not reduced in the presence of
wild-type parkin (Fig. 5I).
Parkin regulates p62 degradation in response
to 6-OHDA
Consistent with previous reports, parkin deﬁcient mice did
not exhibit degeneration of dopaminergic neurons (Goldberg
et al., 2003; Itier et al., 2003; Perez et al., 2005; Perez and
Palmiter, 2005), likely due to the lack of aging related
stresses. Dopamine can covalently modify and inactivate
parkin through its conjugation with cysteine (431) (Lazarou
et al., 2013) at its reactive center or making it becoming
Figure 5. Wild-type parkin, but not disease causing
mutants, ubiquitinates p62. (A) SH-SY5Y cells were trans-
fected with HA-UB together with scramble or parkin siRNAs as
indicated for 36 h. Cells were treated with 5 μmol/L MG132 for
8 h before harvest. Cell lysates were then subjected to
immunoprecipitation and Western blotting to detect the ubiqui-
tination of p62. (B) The midbrain of parkin+/+ or parkin−/− mice,
8-week-old male C57Bl/6, were isolated and homogenized in
lysis buffer. Cell lysates were then subjected to immunoprecip-
itation with anti-p62 antibody and Western blotting to detect the
ubiquitination levels of p62. (C) SH-SY5Y cells were transfected
with HA-UB together with GFP, GFP-parkin or ΔL-R for 36 h,
and were treated with 5 μmol/L MG132 for 8 h before harvest.
Cell lysates were then subjected to immunoprecipitation and
Western blotting for the ubiquitination levels of p62. (D) SH-
SY5Y cells were transfected with HA-UB together with GFP,
GFP-parkin or parkin mutants (T240R, R275 W and C431F).
Cells were treated with 5 μmol/L MG132 for 8 h before harvest.
Cell lysates were then subjected to immunoprecipitation and
Western blotting the ubiquitination levels of p62. (E) SH-SY5Y
cells were transfected with HA-UB together with GFP-parkin
and FLAG-p62 or p62 deletion mutants. Cells were treated with
5 μmol/L MG132 for 8 h before harvest. Cell lysates were then
subjected to immunoprecipitation and Western blotting the
ubiquitination levels of p62. (F) In vitro translated p62 protein
was incubated with commercial puriﬁed ubiquitin, E1, E2
(UbcH7), and bacterially puriﬁed parkin proteins. The reaction
products were analyzed by Western blotting with anti-p62
antibodies. (G) 293T cells were transfected with various HA-UB
constructs (K29, K48 and K63) together with GFP-parkin or
GFP vector. Cells were treated with 5 μmol/L MG132 for 8 h
before harvest. Cell lysates were then subjected to immuno-
precipitation and Western blotting the ubiquitination levels of
p62. (H) 293T cells were transfected with HA-UB together with
GFP-parkin and FLAG-p62 or mutants (K13R, K420R). Cells
were treated with 5 μmol/L MG132 for 8 h before harvest. Cell
lysates were then subjected to immunoprecipitation and
Western blotting the ubiquitination levels of p62. (I) 293T cells
were co-transfected with GFP or GFP-parkin and FLAG-p62 or
K13R/K420R mutants for 24 h. Cells were then harvested and
immunoblotted with anti-FLAG or anti-GFP antibodies. β-Actin
was Western blotted as a loading control.
b
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insoluble that diminishes its activity. As 6-OHDA is widely
used to induce parkinsonal phenotypes in mice, we tested
the functional implication of parkin for PD after 6-OHDA
treatments. Consistent with previous reports (Perez and
Palmiter, 2005), rotation and slip/step analysis do not reveal
PD-like phenotypes in younger mice (6 months) (Fig. S5).
However, such analysis showed that parkin−/− aged mice
(18 months) performed worse than that of wild-type controls
upon injection of 6-OHDA (Fig. 6A). We also observed that
there was pronounced loss of TH positive neurons in parkin
deﬁcient mice compared to its wild-type control after injec-
tions (Fig. 6B and 6C). These data suggest that parkin is of
functional importance for selective loss of dopamingeric
neurons and the onset of PD in aged mice. We further tested
the effects of 6-OHDA on p62 and mitochondrial protein
degradation in vivo. We directly injected 6-OHDA into SN
region and examined the p62 protein levels and found that
p62 levels are increased in wild-type mice, while the levels
were maintained after the treatment with 6-OHDA (Fig. 6D
and 6E). As only small amount of sample can be obtained
from the SN regions of treated mice, we turned to analyze
p62 degradation in response to 6-OHDA treatments in cul-
tured cells. Indeed, treatment of 6-OHDA reduced the protein
levels of parkin (likely due to its self-degradation) and such
treatment signiﬁcantly increased the p62 levels in the insol-
uble fractions in wild-type cells (Fig. 6F). And we also found
the increase of p62 protein levels in parkin−/− MEF cells
compared with the wild type MEF cells (Data not shown).
DISCUSSION
Themajor ﬁndings in our current study are the identiﬁcation of
p62 as a new substrate of parkin and inactivation of parkin
(either by genetic manipulations or enhanced degradation)
may lead to the accumulation of p62 in dopamingeric neuronal
cells and the selective vulnerability of these cells during the
onset of the diseases. It is known that parkin is normally kept in
the inactive state and can be either activated or inactivated
through post-translational modiﬁcation in response to mito-
chondrial or oxidative stresses. Once activated, parkin inter-
acts with and subsequently ubiquitinates p62 at the K13
residue, resulting in the degradation of p62 via the proteaso-
mal-dependent pathway. We found that the degradation of
p62 can be blocked by the proteasomal inhibitor-MG132 even
in Atg5−/− MEF cells (Fig. 3). We clearly showed that p62 is
required to be ubiquitinated by wild-type parkin at the K13
residue and mutation at this site blocked its degradation
(Fig. 5). Recent work by Lee and colleagues suggested that
p62 degradation could be inhibited by the proteasomal inhi-
bitor MG132, which may also block the autophagic activities
(Lee et al., 2012). Our results suggest that both proteasomal
degradation and autophagic degradation are involved in p62
stability since BA1 and other lysosomal inhibitors also pre-
vented its degradation (Fig. 2B). Their relative importance for
p62 stability is likely cellular context and stress type depen-
dent. For instance, mild stress such as hypoxia may promote
p62 degradation in parkin dependent manner (Fig. 1A), while
6-OHDA induced parkin inactivation, p62 accumulation and
aggregation and autophagic degradation (Fig. 6). The exact
detail of how hypoxia activates parkin dependent p62 degra-
dation requires further investigation and we observed the
enhanced ubiquitination of p62 when treated with hypoxia,
which is absent in parkin−/− neuronal cells. Collectively, our
results suggest a new link between these two important
molecules that play essential roles for protein quality control,
mitochondrial dynamics and cell signaling.
Both parkin and p62 were found to play role in mitophagy
and/or general autophagy. In response to the loss of mito-
chondrial membrane potential, PINK1 becomes stabilized at
the outer mitochondrial membrane where it can interact and
phosphorylate parkin for its recruitments and activation at the
site of mitochondria (Kane et al., 2014; Kazlauskaite et al.,
2014; Koyano et al., 2014; Lazarou et al., 2015; Matsuda
et al., 2010; Pickrell and Youle, 2015). Parkin then ubiquiti-
nates a number of mitochondrial membrane proteins, both
p62 and ULK1 are recruited toward mitochondria for selective
cargo recognition (Li et al., 2015). For example, it is sug-
gested that p62 can interact with LC3 for selective cargo
recognition for mitophagy, although the exact role of p62 in
parkin mediated mitophagy remains controversial. Much of
the studies are carried out in the cultured cell system and
physiological relevance of this critical mitophagy pathway
with Parkinson’s diseases needs to be critically evaluated.
Our results suggest that one of the physiological functions of
parkin is to monitor the protein quality of its substrates
through proteasomal degradation, while its mitophagic or
autophagic role occurs under stress conditions such as pro-
tein aggregation or complete loss of mitochondrial membrane
potential (Sterky et al., 2011). Previous studies have shown
that parkin may not translocate onto mitochondria in
response to the loss of mitochondrial membrane potential in
primary neuronal cells (Van Laar et al., 2011) and is dis-
pensable for the progressive mitochondrial respiration deﬁ-
ciency and loss of dopamine neuron caused by the loss of
mtDNA (Sterky et al., 2011). It is possible that, during normal
physiological situations, the parkin/p62 axis is able to keep
cellular p62 levels in check for the well-being of the cell. As
both parkin and p62 are sensitive to oxidative stress and the
perturbation of redox signaling (Jain et al., 2010; LaVoie
et al., 2007), it is possible that, when parkin is mutated or its
E3 ligase activity is inhibited upon oxidative stress, there will
be an increase in the level of p62. This increased level of p62
will initially be protective to the cells for the removal of mis-
folded proteins and protein aggregate through enhanced
protein turnover or selective autophagy. However, drastic and
persistent perturbation of the parkin/p62 axis, would redeﬁne
a threshold where proteins fail to degrade, neuronal signaling
is impaired, and the hallmarks of PD are manifested.
P62 is a multifunctional protein involved in multiple cel-
lular functions such as signal transduction and the degra-
dation of both proteins and organelles. Accumulating protein
aggregates, dysfunctional mitochondria and DNA damage
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Figure 6. Parkin affects p62 degradation in response to 6-OHDA treatments. (A) The parkin+/+and parkin−/− mice, 18-month-old
male C57Bl/6 mice were injured by striatal stereotactic injections with 5.4 μg of 6-OHDA or saline after two weeks, behavioral tests
were carried as described in MATERIALS AND METHODS. (B) The parkin+/+ and parkin−/− mice, 18-month-old male C57Bl/6 mice
were injured by striatal stereotactic injections from one side in brain with 5.4 μg of 6-OHDA or saline after two weeks, and the SN cells
number was detected by immunohistochemical staining using anti-TH antibody antibodies. (C) Analysis of the SN cell number by
Image-J soft was described in (B). (D) The mice described in A were sacriﬁced and the SN regions were isolated, then tissue lysate
was subjected to Western blotting for the indicated protein levels. (E) The relative p62 protein levels were described in (D), which
were normalized to β-actin from 3 separate experiments. (F) The parkin+/+ and parkin−/− MEF cells were treated with 100 μmol/L
6-OHDA for indicated times, both the soluble and insoluble lysate were subjected to Western blotting for the indicated protein levels.
All data are from three independent experiments (n = 7–9 mice). Mean ± SEM, one-way ANOVA, *P < 0.05, **P < 0.01 compared with
control group.
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contribute to the aging process and the onset of age-related
conditions. Alzheimer’s (AD), Parkinson’s (PD), Huntington’s
(HD) and other neurodegenerative diseases are character-
ized by the accumulation of protein aggregates in the brain. A
different aggregation-prone protein characterizes the
pathology of each of these diseases, but virtually all these
protein aggregates associate with p62/SQSTM1. Our results
thus uncover a potential role of parkin-p62 axis for the
selective vulnerability of dopamingeric neuronal cells during
the onset of the diseases. It is interesting that p62 levels are
increased in STR and SN regions in parkin−/−mice, while p62
in the other regions are not (Fig. 1). It was reported that there
is a selective inactivation of parkin in the SN and STR in
sporadic PD through nitrosative and dopaminergic stress in
aged mice (Chung et al., 2004; LaVoie et al., 2005, 2007). It is
thus conceivable that the selective inactivation of parkin in
dopamingeric neurons may result in the accumulation and
aggregation of p62 leading to the inclusion body formation
(Komatsu et al., 2007) and toxic protein aggregation, critical
step for Lewy body formation. We also noticed that aged mice
showed the characteristic phenotype of movement disorder
(Fig. S4), which younger mice have less obvious phenotypes,
suggesting the aged related cellular events, such as protein
oxidation and aggregation, or altered dopamine metabolisms
may be involved (Goldberg et al., 2003), and our data directly
showed that parkin mediated the aggregated p62 degrada-
tion in cells (Fig. S5). During aging, the inactivation of parkin
in dopaminogeric neurons may promote the aggregation of
p62 and neurotoxic proteins for the loss neuronal cells.
Indeed, we observed the increase of insoluble p62 in the
brain of PD patients (data not shown). Thus, our results are
consistent with previous suggestions that inactivation of
parkin is closely associated with the sporadic and progres-
sive nature of PD. Further dissection of how the dysregulated
parkin/p62 axis in dopamigeric neuronal cells will offer new
insights of the molecular pathogenesis of PD and possible
new intervention strategies for ﬁghting PD.
MATERIALS AND METHODS
Cell cultures and plasmids
SH-SY5Y, 293T cells were cultured at 37°C (5% CO2) in DMEM
(GIBCO) supplemented with 10% FBS (HyClone). The mammalian
expression plasmids for GFP-parkin, HA-UB were generated as
described previously (Wang et al., 2011a). The site mutants and
deletion mutants of parkin were generated by PCR with different
primers using pEGFPC1-parkin as template. Full length p62 cDNA
was cloned into the pCMV-tag-2B vector. The deletion mutants of
p62 were generated by PCR with different primers using pCMV-tag-
2B-p62 as a template.
Reagents and antibodies
Antibodies against Myc (Sc-40), GFP (Sc-9996) and HA (Sc-7392)
were purchased from Santa Cruz. Antibodies against p62 (MBL
PM045), β-actin (Sigma A5441), ATG5 (Sigma, A0856), parkin (Cell
Signaling 2132, Millipore AB9244), FLAG (Sigma F1804) were from
the indicated sources.
Transfections and shRNAs
DNA transfections were performed using PEI according to the
manufacturer’s instructions. The target sequences of parkin shRNA







The qPCR primers were as follows: p62-1, CAGAGAATACCT




SH-SY5Y cells transfected with parkin-Myc or Myc-vector grown on
coverslips were washed with phosphate-buffered saline (PBS) and
ﬁxed in 4% formaldehyde in DMEM for 30 min at 37°C. Fixed cells
were permeabilized with 0.2% Triton X-100 in PBS for 5 min at 4°C,
and blocked with 3% BSA in PBS for 1 h. Then cells were stained
with primary antibody (mouse anti-Myc, diluted 1:200; rabbit anti-
p62, diluted 1:700) overnight at 4°C. After washing, cells were
incubated with ﬂuorescein isothiocyanate (FITC)-conjugated anti-
rabbit IgG and Cytm3-linked anti-mouse IgG for 1 h. Unbound anti-
body was removed with PBS, and cells were imaged using a Zeiss
ﬂuorescence microscope.
Western blotting, immunoprecipitation and MBP pull-down
Western blotting, immunoprecipitation and MBP pull-down were per-
formed, as described previously (Wang et al., 2011a). Brieﬂy, cells
were transfectedwith parkin or parkinmutant constructs for 36 h.Cells
were washed with ice-cold PBS and lysed with lysis buffer (pNAS
buffer: 50 mmol/L Tris–HCl [pH 7.5], 150 mmol/L NaCl, 1 mmol/L
EDTA, and 1%Nonidet P-40). The soluble fractions were resolved by
SDS-PAGE and transferred onto nitrocellulose ﬁlter membrane. Blots
were probed with antibodies against p62, GFP, and β-actin. For
immunoprecipitation, cell lysate was incubated with anti-FLAG anti-
body and then protein A/G-agarose beads (Pierce Biotechnology).
The beadswerewashed extensively and boiled in SDS loading buffer,
and the precipitated proteins were detected by Western blotting. For
MBP pull-down, MBP or MBP-parkin fusion protein immobilized on
amylose magnetic beads was incubated with in vitro-translated p62.
The beads were washed and boiled in the SDS loading buffer, and the
precipitated proteins were detected by Western blotting.
The soluble and insoluble cell lysate were prepared in buffer 1%
Trion-100 and 1% SDS buffer described in reference (Kawahara
et al., 2008).
Ubiquitination assays
293T or SH-SY5Y cells were transfected with indicated tagged
constructs in each experiment employing PEI. Cells were treated
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with 5 μmol/L MG132 for 8 h before harvesting. The cells were lysed
for 30 min at 4°C in either pNAS buffer: 50 mmol/L Tris–HCl [pH 7.5],
150 mmol/L NaCl, 1 mmol/L EDTA, and 1% Nonidet P-40 (to detect
noncovalent interaction) or 50 mmol/L Tris [pH 8.0], 150 mmol/L
NaCl, 1% Triton, 0.5% sodium deoxycholate, and 0.1% sodium
dodecyl sulfate (SDS) (to detect covalent interaction), both con-
taining protease inhibitors. Cell lysate was incubated with anti-p62
antibody. The precipitates were subjected to Western blotting with
anti-HA or anti-UB antibodies.
An in vitro ubiquitination assay was performed, as described pre-
viously (Wang et al., 2011a). Brieﬂy, 2 μg MBP, MBP-parkin or MBP-
parkinmutants, expressed and puriﬁed in aE. coli expression system,
was incubated with in vitro translated p62 (2 μg) in 50 μL ubiquitintion
reaction buffer, containing 50 mmol/L Tris–HCl [pH 7.5], 5 mmol/L
MgCl2, 2 mmol/L DTT, 2 mmol/L ATP, 10 μg ubiquitin, 100 ng E1, and
200 ng E2 (UbcH7). Reaction was performed for 2 h at 25°C and
terminated by addition of the SDS loading buffer. The reaction prod-
ucts were then subjected toWestern blotting with anti-p62 antibodies.
Immunocytochemical and histochemicalanalysis
Mice brains were removed and washed with ice-cold PBS. The
brains then were post-ﬁxed with 4% paraformaldehyde for 12 h and
cryoprotected in 30% sucrose. Coronal sections were cut throughout
the midbrain and sections were reacted with rabbit polyclonal anti-
p62 and mouse monoclonal anti-Tyrosine hydroxylase (TH) and
visualized with ﬂuorescein isothiocyanate (FITC)-conjugated anti-
rabbit IgG and cytm3-linked anti-mouse IgG.
Four different brain regions from wild-type or parkin knockout
mice were homogenized in lysis buffer containing 10 mmol/L Tris–
HCl [pH 7.4], 150 mmol/L NaCl, 5 mmol/L EDTA, 0.5% Nonidet P-40,
Phosphate Inhibitor Cocktail I and II (Sigma), and Complete Pro-
tease Inhibitor Mixture (Roche), using homogenizer. After homoge-
nization, samples were rotated at 4°C for 30 min for complete lysis,
then the homogenate was centrifuged at 14,000 rpm for 20 min, and
the resulting fractions were collected and analyzed by immunoblot.
Immunoblotting was performed with an antibody of interest and was
performed with chemiluminescence (Pierce). The densitometric
analyses of the bands were performed using Image-J. Data are
expressed as mean ± SEM. The results were evaluated for statistical
signiﬁcance by applying the unpaired two-tailed Student’s t test.
Mass spectrometry analysis of ubiquitination sites
293Tcells were co-transfected with GFP-parkin and FLAG-p62. Cells
were treated with 5 μmol/L MG132 for 8 h before harvest. Cell lysates
were then subjected to immunoprecipitation with anti-FLAG antibody.
The immunoprecipitates were resolved by SDS-PAGE and visualized
by Coomassie blue staining. Protein samples were reduced, alky-
lated and digested with trypsin. The digests were subsequently
analyzed by liquid chromatography tandem mass spectrometry.
Chronic hypoxia treatments of mice
parkin+/+ or parkin−/− mice (provided by Prof. Zhuohua Zhang from
Central South University) were subjected to a mice hypoxic chamber
for the indicated duration, with an atmosphere of 8% O2 in nitrogen
and free access to food and water.
6-OHDA-lesion model of Parkinson’s disease in mice
Mice were anaesthetized using Chloral hydrate and placed into a
stereotactic frame with nose and ear bars specially adapted for mice.
6-OHDA was dissolved at a concentration of 3 μg/μL saline in 0.1%
ascorbic acid and injected at ﬁnal dosages 5.4 μg. The lesion was
performed using a Hamilton syringe at the following coordinates: AP:
−2.9 mm; ML: +1.3 mm; DV: −4.6 mm. The injection was conducted
at a rate of 0.2 μL/min and the needle was left in place for another
5 min after the injection before it was slowly drawn back. Wound
healing and recovery were monitored after the injection was done.
Animal behavior tests
The methods for the behavioral tests were described previously
(Goldberg et al., 2003).
All animal tests were carried out between 9:00 and 15:00 and
they were scored by the same rater in an observation sound-atten-
uated room under low-intensity light (12 l×), where the mice had
been habituated for at least 1–2 h before the beginning of the tests.
Behavior was monitored through a video camera positioned above
the apparatuses and the videos were later analyzed. The apparatus
were cleaned with 10% ethanol between animals to avoid odor cues.
Brieﬂy a Plexiglass beam consisting of four Sects. (25 cm each, 1 m
total length) of varying width (3.5, 2.5, 1.5, and 0.5 cm) was used.
Individual parkin+/+ or parkin−/− mice were tested after being trained
twice, and their performance was videotaped. The numbers of steps
and slips were counted by viewing the videotapes in slow motion.
Statistical analysis
Statistical analysis between groups was performed by unpaired two-
tailed Student’s t test. Data are presented as mean ± SEM.
ACKNOWLEDGMENTS
We are grateful to Drs. Ted Dawson and Jian Feng for generously
providing the plasmids. We are also grateful to Professor Mark
Bartlam from Nankai University, Tianjin, China for a critical reading of
the manuscript. The research was supported by the National Basic
Research Program (973 Program) (No. 2011CB910903) from MOST
and project (Grant Nos. 81130045, 31471300, 31271529,
301520103904) from the National Natural Science Foundation of
China.
ABBREVIATIONS
6-OHDA, 6-Hydroxydopamine hydrochloride; BA, Baﬁlomycin A1;
CB, cerebellum; CHX, cycloheximide; CTX, frontal cortex; PD,
Parkinson’s disease; PMSF, Pheylmethylsulfonyl ﬂuoride; SDS,
sodium dodecyl sulfate; SN, substantia nigra; STR, striatum; TH,
tyrosine hydroxylase; UB, ubiquitin.
COMPLIANCE WITH ETHICS GUIDELINES
Pingping Song, Shanshan Li, Hao Wu, Ruize Gao, Guanhua Rao,
Dongmei Wang, Ziheng Chen, Biao Ma, Nan Sui, Haiteng Deng,
Zhuohua Zhang, Tieshan Tang, Zheng Tan, Zehan Han, Tieyuan Lu,
Yushan Zhu and Quan Chen declare that they have no conﬂict of









RESEARCH ARTICLE Pingping Song et al.
126
interest with the contents of this article. All institutional and national
guidelines for the care and use of laboratory animals were followed.
AUTHOR CONTRIBUTIONS
P.S, Y.Z and Q.C designed the study and wrote the paper. P.S
performed most of the experiments and data analysis, P.S, S.L, D.W
and Z.C performed the animal experiments and tissues samples
assay, S.L and G.R performed the qPCR for tissues. Y.Z, S.L, N.S
and D.W performed the animal behavior test analysis. Z.T and T.T
performed the animal behavior data analysis and text critical revision.
H.D performed the mass analysis. Z.Z provide the parkin+/− mice. All
authors analyzed the results and approved the ﬁnal version of the
manuscript.
OPEN ACCESS
This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to
the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made.
REFERENCES
Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62
shuttles polyubiquitinated tau for proteasomal degradation.
J Neurochem 94:192–203
Bartlett BJ, Isakson P, Lewerenz J, Sanchez H, Kotzebue RW,
Cumming RC, Harris GL, Nezis IP, Schubert DR, Simonsen A
et al (2011) p62, Ref(2)P and ubiquitinated proteins are con-
served markers of neuronal aging, aggregate formation and
progressive autophagic defects. Autophagy 7:572–583
Bingol B, Tea JS, Phu L, Reichelt M, Bakalarski CE, Song Q,
Foreman O, Kirkpatrick DS, Sheng M (2014) The mitochondrial
deubiquitinase USP30 opposes parkin-mediated mitophagy.
Nature 510:370–375
Biskup S, Gerlach M, Kupsch A, Reichmann H, Riederer P, Vieregge
P, Wullner U, Gasser T (2008) Genes associated with Parkinson
syndrome. J Neurol 255(Suppl 5):8–17
Bjorkoy G, Lamark T, Johansen T (2006) p62/SQSTM1: a missing
link between protein aggregates and the autophagy machinery.
Autophagy 2:138–139
Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular
pathways to neurodegeneration. Nat Med 10(Suppl):S2–S9
Burchell VS, Nelson DE, Sanchez-Martinez A, Delgado-Camprubi
M, Ivatt RM, Pogson JH, Randle SJ, Wray S, Lewis PA, Houlden
H et al (2013) The Parkinson’s disease-linked proteins Fbxo7 and
Parkin interact to mediate mitophagy. Nat Neurosci 16:1257–
1265
Chen Y, Dorn GW 2nd (2013) PINK1-phosphorylated mitofusin 2 is a
Parkin receptor for culling damaged mitochondria. Science
340:471–475
Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L,
Dawson VL, Dawson TM (2004) S-nitrosylation of parkin
regulates ubiquitination and compromises parkin’s protective
function. Science 304:1328–1331
Dawson TM (2007) Unraveling the role of defective genes in
Parkinson’s disease. Parkinsonism Relat Disord 13(Suppl 3):
S248–S249
Dawson TM, Dawson VL (2003) Molecular pathways of neurode-
generation in Parkinson’s disease. Science 302:819–822
Dawson TM, Dawson VL (2010) The role of parkin in familial and
sporadic Parkinson’s disease. Mov Disord 25(Suppl 1):S32–S39
Farrer MJ (2006) Genetics of Parkinson disease: paradigm shifts
and future prospects. Nat Rev Genet 7:306–318
Fecto F, Yan J, Vemula SP, Liu E, Yang Y, Chen W, Zheng JG, Shi Y,
Siddique N, Arrat H et al (2011) SQSTM1 mutations in familial
and sporadic amyotrophic lateral sclerosis. Arch Neurol 68:1440–
1446
Gegg ME, Schapira AH (2011) PINK1-parkin-dependent mitophagy
involves ubiquitination of mitofusins 1 and 2: implications for
Parkinson disease pathogenesis. Autophagy 7:243–245
Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW
(2010) Mitofusin 1 and mitofusin 2 are ubiquitinated in a
PINK1/parkin-dependent manner upon induction of mitophagy.
Hum Mol Genet 19:4861–4870
Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA,
Bhatnagar A, Meloni EG, Wu N, Ackerson LC, Klapstein GJ et al
(2003) Parkin-deﬁcient mice exhibit nigrostriatal deﬁcits but not
loss of dopaminergic neurons. J Biol Chem 278:43628–43635
Ichimura Y, Komatsu M (2010) Selective degradation of p62 by
autophagy. Semin Immunopathol 32:431–436
Ishikawa A, Tsuji S (1996) Clinical analysis of 17 patients in 12
Japanese families with autosomal-recessive type juvenile parkin-
sonism. Neurology 47:160–166
Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme
GA, Laville M, Pratt J, Corti O, Pradier L et al (2003) Parkin gene
inactivation alters behaviour and dopamine neurotransmission in
the mouse. Hum Mol Genet 12:2277–2291
Jain A, Lamark T, Sjottem E, Larsen KB, Awuh JA, Overvatn A,
McMahon M, Hayes JD, Johansen T (2010) p62/SQSTM1 is a
target gene for transcription factor NRF2 and creates a positive
feedback loop by inducing antioxidant response element-driven
gene transcription. J Biol Chem 285:22576–22591
Johnson BN, Berger AK, Cortese GP, Lavoie MJ (2012) The
ubiquitin E3 ligase parkin regulates the proapoptotic function of
Bax. Proc Natl Acad Sci USA 109:6283–6288
Kahle PJ, Haass C (2004) How does parkin ligate ubiquitin to
Parkinson’s disease? EMBO Rep 5:681–685
Kane LA, Lazarou M, Fogel AI, Li Y, Yamano K, Sarraf SA, Banerjee
S, Youle RJ (2014) PINK1 phosphorylates ubiquitin to activate
Parkin E3 ubiquitin ligase activity. J Cell Biol 205:143–153
Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, Mizuno H,
Rockenstein E, Imam SZ, Masliah E (2008) alpha-Synuclein
aggregates interfere with Parkin solubility and distribution: role in
the pathogenesis of Parkinson disease. J Biol Chem 283:6979–
6987
Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS,
Hofmann K, Alessi DR, Knebel A, Trost M, Muqit MM (2014)
Parkin is activated by PINK1-dependent phosphorylation of
ubiquitin at Ser65. Biochem J 460:127–139









Parkin promotes proteasomal degradation of p62 RESEARCH ARTICLE
127
Kirkin V, McEwan DG, Novak I, Dikic I (2009) A role for ubiquitin in
selective autophagy. Mol Cell 34:259–269
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y,
Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations
in the parkin gene cause autosomal recessive juvenile parkin-
sonism. Nature 392:605–608
Ko HS, Kim SW, Sriram SR, Dawson VL, Dawson TM (2006)
Identiﬁcation of far upstream element-binding protein-1 as an
authentic Parkin substrate. J Biol Chem 281:16193–16196
Komatsu M, Ichimura Y (2010) Physiological signiﬁcance of selec-
tive degradation of p62 by autophagy. FEBS Lett 584:1374–1378
Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima
N, Iwata J, Ezaki J, Murata S et al (2007) Homeostatic levels of
p62 control cytoplasmic inclusion body formation in autophagy-
deﬁcient mice. Cell 131:1149–1163
Koyano F, Okatsu K, Kosako H, Tamura Y, Go E, Kimura M, Kimura
Y, Tsuchiya H, Yoshihara H, Hirokawa T et al (2014) Ubiquitin is
phosphorylated by PINK1 to activate parkin. Nature 510:162–166
LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG,
Selkoe DJ (2005) Dopamine covalently modiﬁes and functionally
inactivates parkin. Nat Med 11:1214–1221
LaVoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG
(2007) The effects of oxidative stress on parkin and other E3
ligases. J Neurochem 103:2354–2368
Lazarou M, Narendra DP, Jin SM, Tekle E, Banerjee S, Youle RJ
(2013) PINK1 drives Parkin self-association and HECT-like E3
activity upstreamofmitochondrial binding. J Cell Biol 200:163–172
LazarouM,SliterDA,KaneLA,Sarraf SA,WangCX,BurmanJL, Sideris
DP, Fogel AI, Youle RJ (2015) The ubiquitin kinase PINK1 recruits
autophagy receptors to induce mitophagy. Nature 524:309–314
Lee JT, Wheeler TC, Li L, Chin LS (2008) Ubiquitination of alpha-
synuclein by Siah-1 promotes alpha-synuclein aggregation and
apoptotic cell death. Hum Mol Genet 17:906–917
Lee J, Kim HR, Quinley C, Kim J, Gonzalez-Navajas J, Xavier R,
Raz E (2012) Autophagy suppresses interleukin-1beta (IL-1beta)
signaling by activation of p62 degradation via lysosomal and
proteasomal pathways. J Biol Chem 287:4033–4040
LesageS, Brice A (2009) Parkinson’s disease: frommonogenic forms
to genetic susceptibility factors. Hum Mol Genet 18:R48–R59
Li H, Guo M (2009) Protein degradation in Parkinson disease
revisited: it’s complex. J Clin Investig 119:442–445
Li J, Qi W, Chen G, Feng D, Liu JH, Ma B, Zhou CQ, Mu CL, Zhang
WL, Chen Q et al (2015) Mitochondrial outer-membrane E3
ligase MUL1 ubiquitinates ULK1 and regulates selenite-induced
mitophagy. Autophagy 11:1216–1229
Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billett M,
Landon M, Mayer RJ (1988) Ubiquitin is a common factor in
intermediate ﬁlament inclusion bodies of diverse type in man,
including those of Parkinson’s disease, Pick’s disease, and
Alzheimer’s disease, as well as Rosenthal ﬁbres in cerebellar
astrocytomas, cytoplasmic bodies in muscle, and mallory bodies
in alcoholic liver disease. J Pathol 155:9–15
Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou YS,
Saiki S, Kawajiri S, Sato F et al (2010) PINK1 stabilized by
mitochondrialdepolarization recruitsParkin todamagedmitochondria
and activates latent Parkin for mitophagy. J Cell Biol 189:211–221
Nakaso K, Yoshimoto Y, Nakano T, Takeshima T, Fukuhara Y, Yasui
K, Araga S, Yanagawa T, Ishii T, Nakashima K (2004) Transcrip-
tional activation of p62/A170/ZIP during the formation of the
aggregates: possible mechanisms and the role in Lewy body
formation in Parkinson’s disease. Brain Res 1012:42–51
Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited
selectively to impaired mitochondria and promotes their autop-
hagy. J Cell Biol 183:795–803
Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H,
Overvatn A, Bjorkoy G, Johansen T (2007) p62/SQSTM1 binds
directly to Atg8/LC3 to facilitate degradation of ubiquitinated
protein aggregates by autophagy. J Biol Chem 282:24131–24145
Pankiv S, Lamark T, Bruun JA, Overvatn A, Bjorkoy G, Johansen T
(2010) Nucleocytoplasmic shuttling of p62/SQSTM1 and its role
in recruitment of nuclear polyubiquitinated proteins to promyelo-
cytic leukemia bodies. J Biol Chem 285:5941–5953
Perez FA, Palmiter RD (2005) Parkin-deﬁcient mice are not a robust
model of parkinsonism. Proc Natl Acad Sci USA 102:2174–2179
Perez FA, Curtis WR, Palmiter RD (2005) Parkin-deﬁcient mice are
not more sensitive to 6-hydroxydopamine or methamphetamine
neurotoxicity. BMC neuroscience 6:71
Pickrell AM, Youle RJ (2015) The roles of PINK1, Parkin, and
mitochondrial ﬁdelity in Parkinson’s disease. Neuron 85:257–273
Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, Liani
E, Avraham E, Engelender S (2008) Monoubiquitylation of alpha-
synuclein by seven in absentia homolog (SIAH) promotes its
aggregation in dopaminergic cells. J Biol Chem 283:3316–3328
Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, Fenoglio P,
Grinberg Y, Isaia G, Calvo A, Gentile S et al (2012) SQSTM1
mutations in frontotemporal lobar degeneration and amyotrophic
lateral sclerosis. Neurology 79:1556–1562
Rue L, Lopez-Soop G, Gelpi E, Martinez-Vicente M, Alberch J,
Perez-Navarro E (2013) Brain region- and age-dependent dys-
regulation of p62 and NBR1 in a mouse model of Huntington’s
disease. Neurobiol Dis 52:219–228
Sarraf SA, Raman M, Guarani-Pereira V, Sowa ME, Huttlin EL, Gygi
SP, Harper JW (2013) Landscape of the PARKIN-dependent
ubiquitylome in response to mitochondrial depolarization. Nature
496:372–376
Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR,
Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain
binding protein involved in ubiquitin proteasome degradation. Mol
Cell Biol 24:8055–8068
Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC,
Dawson VL, Dawson TM (2011) PARIS (ZNF746) repression of
PGC-1alpha contributes to neurodegeneration in Parkinson’s
disease. Cell 144:689–702
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S,
Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R
et al (2003) alpha-Synuclein locus triplication causes Parkinson’s
disease. Science 302:841
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R,
Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature
388:839–840
Sriram SR, Li X, Ko HS, Chung KK, Wong E, Lim KL, Dawson VL,
Dawson TM (2005) Familial-associated mutations differentially









RESEARCH ARTICLE Pingping Song et al.
128
disrupt the solubility, localization, binding and ubiquitination
properties of parkin. Hum Mol Genet 14:2571–2586
Sterky FH, Lee S, Wibom R, Olson L, Larsson NG (2011) Impaired
mitochondrial transport and Parkin-independent degeneration of
respiratory chain-deﬁcient dopamine neurons in vivo. Proc Natl
Acad Sci USA 108:12937–12942
Tanaka A, Cleland MM, Xu S, Narendra DP, Suen DF, Karbowski M,
Youle RJ (2010) Proteasome and p97 mediate mitophagy and
degradation of mitofusins induced by Parkin. J Cell Biol
191:1367–1380
Thomas, B., and Beal, M.F. (2007). Parkinson’s disease. Human
molecular genetics 16 Spec No. 2, R183-194
Van Laar VS, Arnold B, Cassady SJ, Chu CT, Burton EA, Berman
SB (2011) Bioenergetics of neurons inhibit the translocation
response of Parkin following rapid mitochondrial depolarization.
Hum Mol Genet 20:927–940
Wang H, Song P, Du L, Tian W, Yue W, Liu M, Li D, Wang B, Zhu Y,
Cao C et al (2011a) Parkin ubiquitinates Drp1 for proteasome-
dependent degradation: implication of dysregulated mitochondrial
dynamics in Parkinson disease. J Biol Chem 286:11649–11658
Wang XN, Winter D, Ashraﬁ G, Schlehe J, Wong YL, Selkoe D, Rice
S, Steen J, LaVoie MJ, Schwarz TL (2011b) PINK1 and Parkin
target miro for phosphorylation and degradation to arrest mito-
chondrial motility. Cell 147:893–906
Wooten MW, Geetha T, Babu JR, Seibenhener ML, Peng J, Cox N,
Diaz-Meco MT, Moscat J (2008) Essential role of sequestosome
1/p62 in regulating accumulation of Lys63-ubiquitinated proteins.
J Biol Chem 283:6783–6789
Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M,
Kenner L, Kleinert R, Prinz M, Aguzzi A, Denk H (2002) p62 Is a
common component of cytoplasmic inclusions in protein aggre-
gation diseases. Am J Pathol 160:255–263









Parkin promotes proteasomal degradation of p62 RESEARCH ARTICLE
129
